PAVmed (PAVM) Stock Rating Reaffirmed by Maxim Group

PAVmed (NASDAQ:PAVM)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a research note issued to investors on Thursday, AnalystRatings.com reports.

The analysts wrote, “Business update call on May 21, 2019, was positive. The initial first-in-human (FIH) CarpX patients were treated successfully without adverse events. the company announced it successfully treated nine patients, of the approximate 20 it expects to treat, in its FIH clinical study, which will be used for its 510(k) re-submission. EsoCheck has completed its largest hurdle, receiving an FDA opinion that it met the substantial equivalent of its predicate. PAVmed reported 1Q19 results and filed its 10-Q on with opex slightly below our estimate and GAAP EPS inline with our expectation.””

Separately, ValuEngine lowered PAVmed from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.

PAVM stock remained flat at $$1.03 on Thursday. The company had a trading volume of 313,985 shares, compared to its average volume of 307,797. PAVmed has a 1-year low of $0.86 and a 1-year high of $1.70.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Thursday, April 4th. The company reported ($0.11) earnings per share (EPS) for the quarter.

An institutional investor recently raised its position in PAVmed stock. Vanguard Group Inc. grew its holdings in PAVmed Inc (NASDAQ:PAVM) by 289.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,712 shares of the company’s stock after purchasing an additional 275,512 shares during the period. Vanguard Group Inc. owned approximately 1.40% of PAVmed worth $482,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.96% of the company’s stock.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

Further Reading: Why do commodities matter?

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.